India’s drug regulator eases norms for use of homegrown COVID-19 vaccine
An expert panel of India’s drug regulator has recommended relaxing norms for the use of a government-backed coronavirus vaccine after it was found to be highly effective in a late-stage trial, the regulator said on its website on Thursday.
For more coronavirus news, visit our dedicated page.
“After detailed deliberation, the committee recommended for omission of the condition of the use of the vaccine in clinical trial mode,” the Central Drugs Standard Control Organization said. “However, the vaccine should be continued to be used under restricted use in emergency situation condition.”
Bharat Biotech’s vaccine showed an 81 percent efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said last week.
For all the latest headlines follow our Google News channel online or via the app.
Indian vaccine giant Serum Inst. warns of supply hit from US raw materials export ban
India seeks investment for vaccine production to match China’s push-source
Huge crowd fetes India PM Narendra Modi at rally for key state poll
Pfizer seeks to make vaccine in India if assured of faster clearance, export freedomPfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance andfreedom on ... Coronavirus
India seeks investment for vaccine production to match China’s push-sourceIndia has urged the United States, Japan and Australia to invest in its vaccine production capacity, an Indian government source told Reuters, as the ... Coronavirus
Indian vaccine giant Serum Inst. warns of supply hit from US raw materials export banA temporary US ban on exports of critical raw materials could limit the production of coronavirus vaccines by companies such as the Serum Institute of ... Coronavirus
Indian firm Bharat Biotech’s COVID-19 vaccine 81 pct effective, shows interim dataBharat Biotech’s vaccine showed 81 percent efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said ... Coronavirus